Safety and efficacy of oral transmucosal fentanyl citrate compared to morphine sulphate immediate release tablet in management of breakthrough cancer pain

• Published in: Indian journal of palliative care 2014-09, Vol.20 (3), p.182-187
• Main Authors: Bhatnagar, Sushma, Devi, Saraswathi, Vinod, Nk, Jain, Pn, Durgaprasad, G, Maroo, Sanjaykumar H, Patel, Ketan R
• Format: Article
• Language: English
• Subjects: Analgesics; Biomedical research; Cancer; Cancer pain; Cancer therapies; Care and treatment; Comparative analysis; Dosage and administration; Drug dosages; Drug therapy; Fentanyl; Health aspects; Morphine; Narcotics; Original; Pain; Pain management; Palliative care; Patient outcomes; Patients; Pharmaceuticals
• ISSN: 0973-1075; 1998-3735
• DOI: 10.4103/0973-1075.138386

To compare the efficacy and safety of oral transmucosal fentanyl citrate (OTFC) and oral morphine in Indian patients with breakthrough episodes of cancer pain. In this randomized, open label, active controlled, clinical study, total 186 patients who regularly experienced 1-4 episodes of breakthrough cancer pain (BTCP) daily, over the persistent pain controlled by taking oral morphine 60 mg/day or its equivalent were randomized to receive either OTFC 200 mcg or oral morphine 10 mg for the treatment of BTCP for 3 days. Improvement in pain as determined by numerical rating scale (NRS) at 5, 15, 30, and 60 minutes of drug administration and percentage of BTCP episodes showing reduction in pain intensity by >33% at 15 minutes were primary efficacy endpoints. Secondary efficacy endpoints were requirement for rescue analgesia and global assessment by physician and patient. Data of both treatment groups were analysed by appropriate statistical test using software, STATISTICA, version 11. Patients treated with OTFC experienced significantly greater improvement in pain intensity of breakthrough episodes compared to those treated with oral morphine at all assessment time points (P < 0.0001). 56% of breakthrough pain episodes treated with OTFC showed a greater than 33% reduction in pain intensity from baseline at 15 minutes compared to 39% episodes treated with oral morphine (P < 0.0001). Patient's and physician's global assessment favoured OTFC than oral morphine (P < 0.0001). Requirement of rescue analgesia in both the study groups was similar (P > 0.05). Both study drugs were well tolerated. OTFC was found to provide faster onset of analgesic effect than immediate release oral morphine in management of breakthrough cancer pain.